A new plan to dramatically accelerate global efforts to end tuberculosis, one of the world’s deadliest and oldest known infectious diseases, was launched Tuesday by the Stop TB Partnership in Jakarta. The fully-costed plan is based on commitments made at a 2018 United Nations High-Level Meeting on Ending TB (UNHLM) to reduce TB deaths by […] Continue reading ->
Nairobi, Kenya (6 December 2019) – An International Conference on Neglected Tropical Diseases (NTDs) ended in Nairobi on Friday with calls for increased research, resources and strengthened cross border partnerships to accelerate the elimination of the diseases. The three day inaugural conference in Africa brought together some 230 participants including scientists, researchers, policy makers and […] Continue reading ->
Madrid, Spain – Heart attacks, respiratory illnesses, and asthma attacks dropped significantly in places as diverse as the United States, China and Europe after new policies reducing air pollution were adopted, and health benefits were sometimes evident in as little as one week after the new policies took effect, according to a new study in […] Continue reading ->
The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading ->
Madrid – Exceptional global heat waves, retreating ice sheets and record sea levels – all driven by rising concentrations of atmospheric greenhouse gases – are the hallmark of the past decade as 2019 draws to a close, said the World Metereological Organization (WMO) on Tuesday. The global average temperature in 2019 (January to October) was […] Continue reading ->
The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading ->